OTCM
BAYRY
Market cap55bUSD
Sep 17, Last price
14.13USD
1D
0.57%
1Q
33.78%
Jan 2017
-45.80%
Name
Bayer AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Related entities
Subsidiaries (114)
Bayer US Finance II LLC
Bayer US Finance LLC
Bayer US Holding LLC
BAYER VAPI PRIVATE LIMITED
Bayer Vital GmbH
BAYER WESTERN PRODUCTION CO., LLC
Bayer World Investments B.V.
Bayer Yakuhin, Ltd.
Bayer Zydus Pharma Private Limited
Biogenetic Technologies B.V.
bris'ath bi xe xr thiy cakad
brisath bi xe xr ho lding (prathesthiy) cakad
BUS C.V.
CONG TY TNHH BAYER VIET NAM
Environmental Science U.S. Inc
KVP Pharma+Veterinär Produkte GmbH
Monsanto Australia Pty Ltd
MONSANTO COMPANY
Monsanto do Brasil Ltda
Monsanto Hungaria Kft.
Key people
Werner Baumann
Chairman of the Management Board, Chief Executive Officer · since 2016
Thomas de Win
Vice Chairman of the Supervisory Board · since 2006
Johannes M. Dietsch
Chief Financial Officer, Member of the Management Board · since 2014
Independent Member of the Supervisory Board · since 2014
Robert Gundlach
Independent Member of the Supervisory Board, Employee Representative · since 2019
Sabine Schaab
Independent Member of the Supervisory Board, Employee Representative · since 2017
Independent Member of the Supervisory Board · since 2018
Headquarters & legal address
Kaiser-Wilhelm-Allee 1
Leverkusen, NW 51373
DE
Leverkusen, NW 51373
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||